Efficacy of 5%, 10% trisodium citrate and heparin as catheter-locking solution for central venous hemodialysis catheters: A prospective randomized study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170314002

Enrollment

249

Registered

2017-03-14

Start date

2016-06-15

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients who need hemodialysis catheter insertion Catheter locking solution Heparin Trisodium citrate Hemodialysis catheter

Interventions

Non&#45

tunnel cuffed catheter: heparin 2&#44

500 u/ml Tunnel&#45

cuffed catheter: heparin 5&#44

000 u/ml as a catheter locking solution,5% trisodium citrate as a catheter locking solution,10% trisodium citrate as a catheter locking solution

Active Comparator Drug,Experimental Drug,Experimental Drug

Heparin,5% trisodium citrate,10% trisodium citrate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age of 18 years, or more - The patients who need hemodialysis catheter insertion (newly insertion of non-tunnel cuff catheter and tunnel-cuff cathterter in appropriate location) and expected to be retained more than 7 days - The patients who have existed tunnel-cuffed catheter and able to obtain blood from catheter lumens at rate more than 250 ml/min

Exclusion criteria

Exclusion criteria: The patients who had - HIT - Allergic to heparin, or trisodium citrate - Pregnancy - Bleeding diathesis - Thrombocytopenia - Hypercoagulable state - Recieved warfarin, enoxaparin, rivaroxaban, apixaban, or dabigatran - Refuse to join the study

Design outcomes

Primary

Measure	Time frame
Catheter dysfunction During 3 months after include into study Obtain blood flow rate less than 250 ml/min, or need rt-PA treatment for catheter dysfunction	—

Secondary

Measure	Time frame
Catheter-related blood stream infection (CRBSI) During 3 months after include into study Rate of CRBSI per 1,000 catheter-day,Exit-site infection During 3 months after include into study Rate of CRBSI per 1,000 catheter-day,All-cause death During 3 months after include into study Rate of CRBSI per 1,000 catheter-day,Side effects (bleeding class 3A-5, and other side effect) During 3 months after include into study Rate of CRBSI per 1,000 catheter-day	—

Measure

Time frame

Catheter-related blood stream infection (CRBSI) During 3 months after include into study Rate of CRBSI per 1,000 catheter-day,Exit-site infection During 3 months after include into study Rate of CRBSI per 1,000 catheter-day,All-cause death During 3 months after include into study Rate of CRBSI per 1,000 catheter-day,Side effects (bleeding class 3A-5, and other side effect) During 3 months after include into study Rate of CRBSI per 1,000 catheter-day

—

Countries

Thailand

Contacts

Public ContactPattharawin Pattharanitima

Unaffiliated

pattharawin@hotmail.com029269793

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026

Efficacy of 5%&#44; 10% trisodium citrate and heparin as catheter&#45;locking solution for central venous hemodialysis catheters: A prospective randomized study